These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 35399952)

  • 1. Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma.
    Gilchrist A; Echeverria SL
    Front Endocrinol (Lausanne); 2022; 13():846310. PubMed ID: 35399952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.
    Dairaghi DJ; Oyajobi BO; Gupta A; McCluskey B; Miao S; Powers JP; Seitz LC; Wang Y; Zeng Y; Zhang P; Schall TJ; Jaen JC
    Blood; 2012 Aug; 120(7):1449-57. PubMed ID: 22618707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCR1 as a target for multiple myeloma.
    Vallet S; Anderson KC
    Expert Opin Ther Targets; 2011 Sep; 15(9):1037-47. PubMed ID: 21609295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays.
    Gilchrist A; Gauntner TD; Fazzini A; Alley KM; Pyen DS; Ahn J; Ha SJ; Willett A; Sansom SE; Yarfi JL; Bachovchin KA; Mazzoni MR; Merritt JR
    Br J Pharmacol; 2014 Nov; 171(22):5127-38. PubMed ID: 24990525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of CCR1 antagonists for multiple myeloma.
    Karash AR; Gilchrist A
    Future Med Chem; 2011 Nov; 3(15):1889-908. PubMed ID: 22023033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.
    Menu E; De Leenheer E; De Raeve H; Coulton L; Imanishi T; Miyashita K; Van Valckenborgh E; Van Riet I; Van Camp B; Horuk R; Croucher P; Vanderkerken K
    Clin Exp Metastasis; 2006; 23(5-6):291-300. PubMed ID: 17086356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCR1 blockade and myeloma bone disease.
    Sebag M
    Blood; 2012 Aug; 120(7):1351-2. PubMed ID: 22899473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
    Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
    Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1.
    Vandyke K; Zeissig MN; Hewett DR; Martin SK; Mrozik KM; Cheong CM; Diamond P; To LB; Gronthos S; Peet DJ; Croucher PI; Zannettino ACW
    Cancer Res; 2017 Oct; 77(20):5452-5463. PubMed ID: 28855206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines.
    Zeissig MN; Hewett DR; Mrozik KM; Panagopoulos V; Wallington-Gates CT; Spencer A; Dold SM; Engelhardt M; Vandyke K; Zannettino ACW
    Leuk Res; 2024 Apr; 139():107469. PubMed ID: 38479337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival.
    Vande Broek I; Leleu X; Schots R; Facon T; Vanderkerken K; Van Camp B; Van Riet I
    Haematologica; 2006 Feb; 91(2):200-6. PubMed ID: 16461304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule antagonist of C-C chemokine receptor 1 (CCR1) reduces disc inflammation in the rabbit model.
    Chou PH; Chee A; Shi P; Lin CL; Zhao Y; Zhang L; An HS
    Spine J; 2020 Dec; 20(12):2025-2036. PubMed ID: 32673730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function.
    Vallet S; Pozzi S; Patel K; Vaghela N; Fulciniti MT; Veiby P; Hideshima T; Santo L; Cirstea D; Scadden DT; Anderson KC; Raje N
    Leukemia; 2011 Jul; 25(7):1174-81. PubMed ID: 21403648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells
    Zeissig MN; Hewett DR; Panagopoulos V; Mrozik KM; To LB; Croucher PI; Zannettino ACW; Vandyke K
    Haematologica; 2021 Dec; 106(12):3176-3187. PubMed ID: 33147936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment.
    Liu L; Yu Z; Cheng H; Mao X; Sui W; Deng S; Wei X; Lv J; Du C; Xu J; Huang W; Xia S; An G; Zhou W; Ma X; Cheng T; Qiu L; Hao M
    Sci Rep; 2020 Nov; 10(1):20508. PubMed ID: 33239656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokines in multiple myeloma.
    Aggarwal R; Ghobrial IM; Roodman GD
    Exp Hematol; 2006 Oct; 34(10):1289-95. PubMed ID: 16982321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the bone marrow microenvironment in multiple myeloma.
    Roodman GD
    J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
    Kyle RA
    Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of chemokine CX3CL1 in progression of multiple myeloma via CX3CR1 in bone microenvironments.
    Wada A; Ito A; Iitsuka H; Tsuneyama K; Miyazono T; Murakami J; Shibahara N; Sakurai H; Saiki I; Nakayama T; Yoshie O; Koizumi K; Sugiyama T
    Oncol Rep; 2015 Jun; 33(6):2935-9. PubMed ID: 25962684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.